Machine learning enables de novo multiepitope design of <i>Plasmodium falciparum</i> circumsporozoite protein to target trimeric L9 antibody.

ABSTRACT: Currently approved vaccines for the prevention of malaria provide only partial protection against disease due to high variability in the quality of induced antibodies. These vaccines present the unstructured central repeat region, as well as the C-terminal domain, of the circumsporozoite protein (PfCSP) of the malaria parasite, Plasmodium falciparum [K. L. Williams et al., Nat. Med. 30,1-13 (2024)]. A recently discovered protective monoclonal antibody, L9, recognizes three structured copies of the PfCSP minor repeat. Similarly to other highly potent antimalarial antibodies, L9 relies on critical homotypic interactions between antibodies for its high protective efficacy [P. Tripathi et al., Structure 31, 480-491.e4 (2023); G. M.

SUBMITTER: Nelson JAD 

PROVIDER: S-EPMC12704715 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature